In addition, a previous study found that NLR, as well as patient perception of pain, may help predict sustained remission with even better validity than CRP, ESR, and disease activity scores.[46] Boulos et al[47] identified higher NLR at baseline as an independent predictor of failure of triple therapy (methotrexate-sulfasalazine-hydroxychloroquine) in RA (OR = 2.65, P = .01, 95% CI = 1.23–5.72, AUG of 0.63), a predictive property that is unique to NLR and superior to traditional markers of disease activity. This evidence concerns the gene CRP and rheumatoid arthritis.